

11. 10
82. The method according to claim ~~81~~¹⁰ wherein said
TGF- β_3 is provided at said site in an inactive form that is
converted to an active form at said site.

I1
Carls
12. 10
83. The method according to claim ~~81~~¹⁰ wherein said
TGF- β_3 is provided at said site in a pharmaceutical
composition comprising a pharmaceutically acceptable
carrier.--

REMARKS

Reconsideration of this application and entry of the
foregoing amendments are respectfully requested.

The claims have been revised so as to define the
invention with additional clarity. That the claims have
been amended should not be construed as an indication that
Applicants agree with any view expressed by the Examiner.
Rather the revisions are offered merely to advance
prosecution and Applicants reserve the right to pursue any
deleted subject matter in a continuation application.

Claims 56-71 stand rejected under 35 USC 112, first
paragraph, as allegedly being non-enabled. Withdrawal of
the rejection is submitted to be in order in view of the
above-noted claim revisions and for the reasons that
follow.

The Examiner will appreciate that reference is not made in the claims as now presented to ribozymes or anti-sense or soluble receptors.

As regards the remaining aspects of the rejection, the Examiner's attention is drawn to the specification for evidence relating to the anti-fibrotic effects of TGF- β 3 and Shah et al on page 2 of the specification (copy enclosed). Further evidence relating to the effect of anti-PDGF antibodies is also contained within the enclosed abstract published in the Journal of Cellular Biochemistry.


In view of the above, reconsideration is requested.

This application is submitted to be in condition for allowance and a Notice to that effect is requested.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

By



Mary J. Wilson

Reg. No. 32,955

MJW:tat

1100 North Glebe Road
8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100